MolPharm xPharm- The Comprehensive Pharmacology Reference

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Klopman, G.
Right arrow Articles by Ramu, A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Klopman, G.
Right arrow Articles by Ramu, A.

0026-895X/97/020323-12$3.00/0
Copyright © by The American Society for Pharmacology and Experimental Therapeutics
All rights of reproduction in any form reserved.
MOLECULAR PHARMACOLOGY 52:323-334 (1997).

Quantitative Structure-Activity Relationship of Multidrug Resistance Reversal Agents

Gilles Klopman, Leming M. Shi, and Avner Ramu

Department of Chemistry, Case Western Reserve University, Cleveland, Ohio 44106 (G.K., L.M.S.), and Cancer Center for Hematology, Texas Children's Hospital, M/C3 3320, Houston, Texas 77030 (A.R.)

Multidrug resistance (MDR) is one of the major obstacles to long term successful cancer chemotherapy. The use of MDR reversal (MDRR) agents is a promising approach to overcome the undesired MDR phenotype. To design more effective MDRR agents that are urgently needed for clinical use, a data set of 609 diverse compounds tested for MDRR activity against P388/ADR-resistant cell lines was submitted to the MULTICASE computer program for structure-activity analysis. Some substructural features related to MDRR activity were identified. For example, the CH2-CH2-N-CH2-CH2 group was found in most of the active compounds, and the activity was further enhanced by the presence of (di)methoxylphenyl groups, whereas the presence of a stable quaternary ammonium salt, a carboxylic, a phenol, or an aniline group was found to be detrimental to activity. Possible explanations for these observations are proposed. Some physicochemical properties, e.g., the partition coefficient (log P) and the graph index (which in some sense measures the "complexity" of a molecule) were also found to be relevant to activity. Their role in MDRR was also rationalized. Based on our quantitative structure-activity relationship study of MDRR agents, some compounds with desired substructural features and activity were identified from the MACCS-II and National Cancer Institute DIS databases and tested experimentally. Our study may also help the rational design of anti-cancer drugs. Based on this study and on observations by other researchers, we postulate that P-glycoprotein-mediated resistance to paclitaxel could probably be eliminated by proper substitution of its benzamido and phenyl groups. Several novel compounds with the paclitaxel skeleton are proposed, which may lead to a new generation of paclitaxel anti-cancer drugs with less MDR potential.

Copyright © by The American Society for Pharmacology and Experimental Therapeutics


This article has been cited by other articles:


Home page
 J. Pharmacol. Exp. Ther.Home page
H. Saito, H. Hirano, H. Nakagawa, T. Fukami, K. Oosumi, K. Murakami, H. Kimura, T. Kouchi, M. Konomi, E. Tao, et al.
A New Strategy of High-Speed Screening and Quantitative Structure-Activity Relationship Analysis to Evaluate Human ATP-Binding Cassette Transporter ABCG2-Drug Interactions
J. Pharmacol. Exp. Ther., June 1, 2006; 317(3): 1114 - 1124.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Pharmacol.Home page
A. Garrigues, N. Loiseau, M. Delaforge, J. Ferte, M. Garrigos, F. Andre, and S. Orlowski
Characterization of Two Pharmacophores on the Multidrug Transporter P-Glycoprotein
Mol. Pharmacol., December 1, 2002; 62(6): 1288 - 1298.
[Abstract] [Full Text] [PDF]

Home page
 Drug Metab. Dispos.Home page
E.-j. Wang, C. N. Casciano, R. P. Clement, and W. W. Johnson
Evaluation of the Interaction of Loratadine and desloratadine with P-glycoprotein
Drug Metab. Dispos., August 1, 2001; 29(8): 1080 - 1083.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
Q. Mi, B. Cui, G. L. Silva, D. Lantvit, E. Lim, H. Chai, M. You, M. G. Hollingshead, J. G. Mayo, A. D. Kinghorn, et al.
Pervilleine A, a Novel Tropane Alkaloid that Reverses the Multidrug-resistance Phenotype
Cancer Res., May 1, 2001; 61(10): 4030 - 4037.
[Abstract] [Full Text]

Home page
 Mol. Pharmacol.Home page
C. Rousselle, P. Clair, J.-M. Lefauconnier, M. Kaczorek, J.-M. Scherrmann, and J. Temsamani
New Advances in the Transport of Doxorubicin through the Blood-Brain Barrier by a Peptide Vector-Mediated Strategy
Mol. Pharmacol., April 1, 2000; 57(4): 679 - 686.
[Abstract] [Full Text]

Home page
 Mol. Pharmacol.Home page
G. Ecker, M. Huber, D. Schmid, and P. Chiba
The Importance of a Nitrogen Atom in Modulators of Multidrug Resistance
Mol. Pharmacol., October 1, 1999; 56(4): 791 - 796.
[Abstract] [Full Text]

Home page
 Mol. Pharmacol.Home page
L. M. Shi, T. G. Myers, Y. Fan, P. M. O'Connor, K. D. Paull, S. H. Friend, and J. N. Weinstein
Mining the National Cancer Institute Anticancer Drug Discovery Database: Cluster Analysis of Ellipticine Analogs with p53-Inverse and Central Nervous System-Selective Patterns of Activity
Mol. Pharmacol., February 1, 1998; 53(2): 241 - 251.
[Abstract] [Full Text]


Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
Molecular Interventions Drug Metabolism and Disposition

Copyright © 1997 by the American Society for Pharmacology and Experimental Therapeutics